Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: Improvement with corticosteroid treatment

Journal of Internal Medicine

Volumn 272, Issue 2, 2012, Pages 177-184

  Pirro, M ^a   Bocci, E B ^a   Di Filippo, F ^a   Schillaci, G ^a   Mannarino, M R ^a   Bagaglia, F ^a   Gerli, R ^a   Mannarino, E ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Corticosteroid; Endothelial microparticles; Endothelial progenitor cells; Polymyalgia rheumatica

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; PREDNISONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CELL REGENERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM INJURY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA;

ADRENAL CORTEX HORMONES; AGED; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; DRUG MONITORING; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; POLYMYALGIA RHEUMATICA; REGENERATION; TREATMENT OUTCOME;

EID: 84864297752     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02510.x     Document Type: Article

References (45)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-71.
2. Bernatsky S, Joseph L, Pineau CA et al. Polymyalgia rheumatica prevalence in a population-based sample. Arthritis Rheum 2009; 61: 1264-7.
3. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
4. St-Pierre AC, Cantin B, Bergeron J et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 2005; 182: 315-21.
5. Pirro M, Bergeron J, Dagenais GR et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001; 161: 2474-80.
6. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011; 27: 174-82.
7. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006; 5: 331-7.
8. Maradit Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population based study. Arthritis Rheum 2005; 52: 722-32.
9. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res 2011; 63: 178-83.
10. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic disorders. Circulation 2005; 112: 3337-47.
11. Warrington KJ, Jarpa EP, Crowson CS et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res Ther 2009; 11: R50.
12. Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 2005; 53: 578-84.
13. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995; 34: 261-4.
14. Mannarino E, Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology 2008; 59: 69S-72S.
15. Pirro M, Schillaci G, Paltriccia R et al. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 2530-5.
16. Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George F. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J Cell Mol Med 2009; 13: 454-71.
17. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 27-33.
18. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
19. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
20. van Zonneveld AJ, de Boer HC, van der Veer EP, Rabelink TJ. Inflammation, vascular injury and repair in rheumatoid arthritis. Ann Rheum Dis 2010; 69(Suppl 1): i57-60.
21. Duval A, Helley D, Capron L et al. Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology (Oxford) 2010; 49: 1049-55.
22. Westerweel PE, Verhaar MC. Endothelial progenitor cell dysfunction in rheumatic disease. Nat Rev Rheumatol 2009; 5: 332-40.
23. Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 2010; 49: 186-90.
24. Michet CJ, Matteson EL. Polymyalgia rheumatica. BMJ 2008; 336: 765-9.
25. Girod JP, Brotman DJ. Does altered corticosteroid homeostasis increase cardiovascular risk? Cardiovasc Res 2004; 64: 217-26.
26. Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM IIIrd, Hunder GG, Gabriel SE. Corticosteroids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007; 57: 279-86.
27. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80.
28. Bernal-Mizrachi L, Jy W, Jimenez JJ et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-70.
29. Pirro M, Schillaci G, Romagno PF et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther 2009; 14: 14-21.
30. Chirinos JA, Zambrano JP, Virani SS et al. Correlation between apoptotic endothelial microparticles and serum interleukin-6 and C-reactive protein in healthy men. Am J Cardiol 2005; 95: 1258-60.
31. Tousoulis D, Andreou I, Antoniades C, Tentolouris C, Stefanadis C. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: therapeutic implications for cardiovascular diseases. Atherosclerosis 2008; 201: 236-47.
32. Mayr FB, Spiel AO, Leitner JM, Firbas C, Sieghart W, Jilma B. Effects of low dose endotoxemia on endothelial progenitor cells in humans. Atherosclerosis 2007; 195: e202-6.
33. Combes V, Simon AC, Grau GE et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
34. Verma S, Kuliszewski MA, Li SH et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058-67.
35. Leroyer AS, Anfosso F, Lacroix R et al. Endothelial-derived microparticles: biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost 2010; 104: 456-63.
36. Gonzalez-Gay MA, Agudo M, Martinez-Dubois C, Pompei O, Blanco R. Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 2010; 11: 1077-87.
37. Walker BR. Corticosteroids and cardiovascular disease. Eur J Endocrinol 2007; 157: 545-59.
38. Davis JM IIIrd, Maradit Kremers H, Crowson CS et al. Corticosteroids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56: 820-30.
39. Asai K, Funaki C, Hayashi T et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb 1993; 13: 892-9.
40. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Sanchez-Andrade A, Martín J, Gonzalez-Gay MA. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. J Rheumatol 2006; 33: 74-8.
41. Pirro M, Schillaci G, Savarese G et al. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 2004; 34: 335-41.
42. Pirro M, Schillaci G, Bagaglia F et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008; 197: 757-67.
43. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32: 2034-41.
44. Schmidt-Lucke C, Rössig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
45. Lorenzen J, David S, Bahlmann FH et al. Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease - a prospective follow-up study. PLoS One 2010; 5: e11477.